INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc.

Pomerantz LLP is investigating whether EyePoint and certain officers or directors engaged in securities fraud or other unlawful practices; the allegations have not been established. EyePoint’s DURAVYU failed to meet key efficacy endpoints in two Phase 3 wet AMD trials: its shares fell 66.98% to $4.87 on Aug. 17, 2026, and 85.28% to $0.44 on Oct. 19. After the second trial failure, the company said it would terminate its late-stage wet AMD program and cut its workforce by 53%, while restructuring around diabetic macular edema programs.

Analysis

The lawsuit announcement adds little fundamental information beyond the clinical failures already reflected in EYPT’s severe repricing; a law firm’s investigation is not evidence of misconduct or a reliable indicator of eventual damages. Near term, the bigger market risk is residual financing and liquidity uncertainty in a sub-$1 biotech after a major restructuring—not incremental revenue loss to REGN, whose Eylea franchise is far larger in scope than this single competitor’s failed program. Treat any read-through to REGN as negligible absent evidence of meaningful patient or share capture.

Over the next 1–3 months, EYPT’s valuation is likely to hinge on verified cash runway, restructuring costs, and whether its remaining diabetic macular edema programs have credible timelines and funding. Those details are not provided. The 6–18 month upside case is retained pipeline optionality; the downside is that reduced staffing and capital constrain development before those programs generate decision-useful data. Litigation could become more material if specific allegations or evidence emerge, but the current solicitation alone does not establish that.

Contrarian point: the legal headline may prompt another reflexive selloff, but the core clinical repricing has already occurred. That does not make EYPT cheap: with limited data on cash, dilution risk, and the remaining pipeline, apparent low nominal price is not a valuation floor.

Key Decisions for Investors

• No trade on the Pomerantz notice alone. Avoid chasing an EYPT short after the extreme repricing; low-priced biotech shares can be illiquid and vulnerable to sharp squeezes, while the remaining pipeline and balance-sheet facts are missing.
• For existing EYPT exposure, treat cash runway, restructuring charges, financing or dilution disclosures, and DME trial timelines as the decision variables. Reassess if filings or guidance show runway materially shorter than expected or development plans delayed; do not infer a recovery from the lawsuit headline fading.
• Keep REGN exposure tied to its own Eylea and broader operating outlook rather than this event. The thesis that EYPT’s setback supports REGN would be falsified as a trade catalyst if there is no evidence of meaningful patient switching or incremental sales.
• Monitor for a filed complaint with specific, substantiated allegations and for any company disclosure about prior knowledge or corrective statements. Until then, classify litigation as a secondary, potentially months-to-years risk rather than a new near-term fundamental catalyst.